NASDAQ$ALEC
Alector Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Alector reported first quarter results, highlighting progress in clinical trials and executive leadership.
Alector reported a net loss of $44.6 million for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $868.6 million as of March 31, 2022, expected to fund operations into mid-2024. Significant progress was made in clinical trials, particularly with latozinemab in FTD-C9orf72 patients.
- INFRONT-2 Phase 2 clinical trial data showed a trend towards an annual delay in disease progression of approximately 54 percent in FTD-C9orf72 patients treated with AL001 (latozinemab).
- Treatment with latozinemab resulted in a two- to three-fold increase in progranulin above physiological levels.
- Gary Romano, M.D., Ph.D., was appointed as Chief Medical Officer, and Marc Grasso, M.D., joined as Chief Financial Officer.
- Cash, cash equivalents, and marketable securities totaled $868.6 million, providing a runway into mid-2024.
Headline financials
Revenue & EPS history
Alector · Revenue · Quarterly
$24.5M
Revenue by segment
Alector · $24.5M total across 1 segment · Q1 2022
- Collaboration Revenue$24.5M+495.5%100.0%
Forward guidance
Alector anticipates continued progress across its progranulin franchise and Alzheimer's and oncology programs. They expect to initiate a Phase 1 trial for AL044 in the second half of 2022 and a Phase 1 trial for AL009 within the next year.
Tailwinds
- Advancing and expanding progranulin franchise
- Ongoing INVOKE-2 Phase 2 clinical trial evaluating AL002
- Expected initiation of Phase 1 trial for AL044 in the second half of 2022
- Presented preclinical data from AL009 immuno-oncology program
- Phase 1 trial of AL009 expected to begin within the next year
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+1.1%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-5.5%
Avg return
30 days after
52%
15 / 29 earnings
Positive
+32.9%
Q2 2023
Best reaction
-18.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -16.0% | -36.6% | |
| Q4 2025 | +7.1% | -11.7% | -16.3% | |
| Q3 2025 | +4.1% | +8.4% | -2.8% | |
| Q1 2025 | +4.2% | +7.4% | +23.8% | |
| Q4 2024 | -3.5% | -15.4% | -25.0% | |
| Q3 2024 | +12.8% | +21.3% | -56.8% | |
| Q2 2024 | +0.8% | +0.9% | -4.2% | |
| Q1 2024 | -1.9% | +1.7% | -17.7% | |
| Q4 2023 | +7.9% | +14.4% | -7.1% | |
| Q3 2023 | -2.6% | -17.7% | +6.0% | |
| Q2 2023 | +32.9% | +12.4% | -15.6% | |
| Q1 2023 | +13.0% | +20.6% | +8.5% | |
| Q4 2022 | +0.9% | -9.5% | -30.3% | |
| Q3 2022 | -18.4% | +3.1% | +3.1% | |
| Q2 2022 | +16.3% | +12.7% | -6.9% | |
| Q1 2022 | -12.7% | -20.0% | -11.9% | |
| Q4 2021 | +1.9% | -1.3% | -7.8% | |
| Q3 2021 | +2.3% | +4.1% | -20.7% | |
| Q2 2021 | +9.5% | +9.0% | +10.1% | |
| Q1 2021 | -7.8% | -12.4% | +6.1% | |
| Q4 2020 | -4.7% | -10.7% | -14.3% | |
| Q3 2020 | +0.4% | +7.2% | +25.2% | |
| Q2 2020 | -6.9% | -7.4% | -13.5% | |
| Q1 2020 | -5.0% | +0.3% | +3.7% | |
| Q4 2019 | -1.5% | -4.4% | +0.8% | |
| Q3 2019 | -6.1% | -4.2% | +19.5% | |
| Q2 2019 | -1.7% | -18.0% | +9.4% | |
| Q1 2019 | +4.9% | +1.3% | +0.2% | |
| Q4 2018 | -8.6% | -3.5% | +10.8% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro